{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:41:04Z","timestamp":1697002864713},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T00:00:00Z","timestamp":1148428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine differences among four protease inhibitor (PI)\u2010based drug regimens in adherence to therapy and rate of achievement of virological suppression in a cohort of antiretroviral\u2010naive patients initiating highly active antiretroviral therapy (HAART).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants were antiretroviral\u2010naive and were first dispensed combination therapy containing two nucleosides and a ritonavir (RTV)\u2010boosted PI, or unboosted nelfinavir, between 1 January 2000 and 30 September 2003. Logistic regression analysis was used to examine associations between the prescribed PI and other baseline factors associated with being &gt;90% adherent to therapy and then to determine the associations of prescribed drug regimen, adherence to therapy and baseline variables with the odds of achieving two consecutive viral loads of &lt;500 HIV\u20101 RNA copies\/mL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 385 subjects were available for analysis. Lopinavir (LPV)\/RTV was prescribed for 168 patients (42% of total); 86 (22%) received indinavir (IDV)\/RTV; 91 (24%) received nelfinavir (NFV) and 40 (10%) received saquinavir (SQV)\/RTV. SQV\/RTV\u2010based HAART was associated with reduced adherence to therapy [odds ratio (OR)=0.40; 95% confidence interval (CI) 0.19\u20130.83]. In multivariate models, IDV\/RTV (OR=0.45; 95% CI 0.22\u20130.92), SQV\/RTV (OR=0.18; 95% CI 0.07\u20130.43) and NFV were associated with reduced odds of achieving virological suppression within 1 year in comparison to LPV\/RTV\u2010based therapy. For patients receiving NFV, adjusting for adherence (OR=0.73; 95% CI 0.36\u20131.47) rendered this association nonsignificant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients prescribed IDV\/RTV, NFV or SQV\/RTV were less likely to achieve virological suppression on their first regimen compared with patients prescribed LPV\/RTV. Reduced adherence to these therapies only partly explained these observed differences.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2006.00381.x","type":"journal-article","created":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T08:22:49Z","timestamp":1148458969000},"page":"311-316","source":"Crossref","is-referenced-by-count":9,"title":["Regimen\u2010dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor\u2010based highly active antiretroviral therapy"],"prefix":"10.1111","volume":"7","author":[{"given":"DM","family":"Moore","sequence":"first","affiliation":[]},{"given":"RS","family":"Hogg","sequence":"additional","affiliation":[]},{"given":"B","family":"Yip","sequence":"additional","affiliation":[]},{"given":"E","family":"Wood","sequence":"additional","affiliation":[]},{"given":"M","family":"Harris","sequence":"additional","affiliation":[]},{"given":"JSG","family":"Montaner","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2006,5,24]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199906180-00014"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200003100-00008"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00015"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200205030-00012"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199909100-00021"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350400900314","article-title":"Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver","volume":"9","author":"Kerr T","year":"2004","journal-title":"Antiviral Ther"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200312050-00010"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012354"},{"key":"e_1_2_6_10_2","first-page":"635","article-title":"Randomized trial to evaluate indinavir\/ritonavir versus saquinavir\/ritonavir in human immunodeficiency virus type 1\u2010infected patients","volume":"188","author":"Dragsted UB","year":"2003","journal-title":"the MaxCmin1 Trial"},{"key":"e_1_2_6_11_2","unstructured":"HarrisM PressN ThorneAet al. Results of simplified protease inhibitor trial. Antiviral effects of once daily saquinavir SGC plus ritonavir vs twice daily indinavir plus ritonavir.12th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2005 [Abstract 574]."},{"key":"e_1_2_6_12_2","unstructured":"SmithC SabinCA JohnsonMet al. Participation in randomized clinical trials at the Royal Free Hospital. Characteristics of those included and effect on treatment outcomes.12th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2005 [Abstract 618]."},{"key":"e_1_2_6_13_2","first-page":"400","article-title":"Evidence\u2010based public health","volume":"94","author":"Victora CG","year":"2004","journal-title":"moving beyond randomized trials"},{"key":"e_1_2_6_14_2","first-page":"222","article-title":"Antiretroviral treatment for adult HIV infection in 2002","volume":"288","author":"Yeni PG","year":"2002","journal-title":"updated recommendations of the International AIDS Society-USA Panel"},{"key":"e_1_2_6_15_2","first-page":"265","article-title":"Once\u2010daily versus twice\u2010daily lopinavir\/ritonavir in antiretroviral\u2010naive HIV\u2010positive patients","volume":"189","author":"Eron JJ","year":"2004","journal-title":"a 48-week randomized clinical trial"},{"key":"e_1_2_6_16_2","first-page":"53","article-title":"Lopinavir\/ritonavir vs. indinavir\/ritonavir in antiretroviral naive HIV\u2010infected patients","volume":"62","author":"Bongiovanni M","year":"2004","journal-title":"immunovirological outcome and side effects"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1310\/HVQX-7Q27-X4V1-GJA1"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-10-200311180-00008"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2006.00381.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2006.00381.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T18:06:39Z","timestamp":1696961199000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2006.00381.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,24]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1468-1293.2006.00381.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2006.00381.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,24]]}}}